NASDAQ · CDNA

CareDx, Inc.

$37.14 -$0.47 (-1.25%) 1D After hours

Key Metrics

$1.94B
Market cap
P/E · TTM
$412.82M
Revenue · TTM
−$8.19M
Net income
EPS · TTM $-0.15
Dividend yield
Free cash flow
Beta · 1Y 1.18
EBITDA · TTM $7.31M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    The stock moved +35.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 16
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Apr 16
    The stock moved +27.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 16

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.94B
Enterprise value
Shares outstanding51.7M
52-wk range$11.26 – $40.47
Avg volume · 20D907.0K
Net cash
Book value / share$5.67
IndustryServices-Medical Laboratories
ExchangeNASDAQ
About CareDx, Inc.
IPO dateJul 17, 2014
Employees765

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S4.71
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating -1.9%
Net -2.0%
FCF
ROE / ROIC -2.4% · -6.5%

Financial Health

Current ratio3.40
Quick ratio3.07
Debt / equity
Debt / EBITDA
Net cash
Working capital$190.24M

Cash Flow · TTM

Operating CF $72.95M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

11.0
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings